Robyn O'Brien joined the Liu Idea Lab of Innovation and Entrepreneurship to discuss how she's found success in advocating for change with her latest startup. Photo via robynobrien.com

Robyn O'Brien, co-founder of rePlant Capital and Rice adjunct professor, joined the Liu Idea Lab for Innovation and Entrepreneurship for the first virtual Ladies who LaUNCH. RePlant Capital is working with food industry players to invest in resilient and sustainable agricultural practices. She continues working toward her goal to "make clean and safe food affordable and accessible to anyone who wants it."

After receiving an MBA from Rice, O'Brien found herself thrust into the world of food as a financial analyst. Years later when her one-year old child had a severe allergic reaction, Robyn's previous work experience in the food industry suddenly became much more personal. She dug into the data and unearthed injustice hidden in the US food industry, resulting in her book, The Unhealthy Truth. She brought to light some shocking realities about the rise in food related allergies in the US and the double standards of food quality in the US versus other international markets. Companies were selling one product in Europe with wholesome ingredients, while "the same" product in the US was made of artificial ingredients and chemicals.

As a rebel-rousing public figure, Robyn has received her fair share of push back, but she has come out of the storm more resilient and compassionate because of it. Over the course of her hour-long talk, Robyn shared some of the ways that she has been able to advocate for change, as a mom up against industry giants and those with power to silence her. A few of the strategies she has found to be fool proof are:

1. Although her story about the US food market is quite shocking, O'Brien explained that she has lead and advocated from a place of love, not fear. O'Brien reminds us, "The reason we're hurting… is because we love." Whether she's communicating with a national audience or working on a team, Robyn has found success by turning to empathy and encourages us to do the same. Even internally, when there is discourse in her team, she says, "Start with compassion."

2. Lead with data. Despite how personal the issue felt to Robyn and the anger we are justified in feeling about this issue, Robyn continually relies on the data to do the convincing as opposed to an emotional response. "Don't exaggerate… data will tell it's own story." She encourages us to do our homework, know our facts, and walk into meetings confidently.

3. You have to exercise courage daily. ""Courage is a muscle. The more you use it, the stronger it gets." And when your internal meter senses something is misaligned, listen to it. There is room for change in departments and large organizations and it takes courage to address these issues. But it also takes courage to recognize the "gut check" and acknowledge when the misalignment is too great, and to walk away.

O'Brien is a great example of sticking to your guns, even when you're up against a global industry. Now, I leave you with the challenge of taking smaller steps – plant seeds of change where you are and advocate for individuals in need.

------

This article originally appeared on Liu Idea Lab for Innovation & Entrepreneurship's blog.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.